Falling through the cracks: New zealand prostate cancer survivors’ experiences and views regarding PSA testing
Date of this Version
Letter to the Editor
Prostate cancer (PCa) is the most common male cancer in many countries. The 5-
year survival rates for PCa are rising, with this thought to reflect improvements in
early detection via prostate-specific antigen (PSA) testing and improved outcomes
from treatment options. However, there are also risks associated with PSA testing,
such as misdiagnosis and harmful side-effects from various treatments that may
outweigh any potential benefits, especially for older men.
This document is currently not available here.
This document has been peer reviewed.